Effectiveness and Safety of Adipose-Derived Regenerative Cells for the Treatment of Critical Lower Limb Ischemia
Sponsor: Central Clinical Hospital w/Outpatient Health Center of Business Administration for the President of Russian Federation
Listed as NCT02864654, this PHASE1/PHASE2 trial focuses on Arteriosclerosis Obliterans and Critical Limb Ischemia and remains ongoing. Sponsored by Central Clinical Hospital w/Outpatient Health Center of Business Administration for the President of Russian Federation, it has been updated 8 times since 2016, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Unknown PHASE1/PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Unknown PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE1/PHASE2
Status: Unknown Status → Unknown · Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE1_PHASE2
-
Sep 2018 — Jan 2021 [monthly]
Unknown Status PHASE1_PHASE2
Status: Enrolling By Invitation → Unknown Status
▶ Show 3 earlier versions
-
Jun 2018 — Sep 2018 [monthly]
Enrolling By Invitation PHASE1_PHASE2
-
Oct 2017 — Jun 2018 [monthly]
Enrolling By Invitation PHASE1_PHASE2
-
Jan 2017 — Oct 2017 [monthly]
Enrolling By Invitation PHASE1_PHASE2
First recorded
Jul 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Central Clinical Hospital w/Outpatient Health Center of Business Administration for the President of Russian Federation
For direct contact, visit the study record on ClinicalTrials.gov .